Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
6.40B | 6.26B | 6.17B | 6.30B | 8.10B | Gross Profit |
3.71B | 3.75B | 3.88B | 3.92B | 4.75B | EBIT |
1.49B | 1.33B | 1.48B | 1.62B | 2.85B | EBITDA |
1.60B | 1.44B | 1.69B | 1.81B | 2.99B | Net Income Common Stockholders |
864.00M | 1.02B | 917.00M | 1.35B | 2.16B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
675.00M | 693.00M | 706.00M | 737.00M | 500.00M | Total Assets |
13.10B | 12.06B | 10.96B | 10.68B | 10.43B | Total Debt |
8.88B | 8.76B | 8.91B | 9.13B | 31.00M | Net Debt |
8.21B | 8.07B | 8.21B | 8.40B | -469.00M | Total Liabilities |
12.63B | 12.13B | 11.85B | 12.19B | 11.25B | Stockholders Equity |
472.00M | -70.00M | -892.00M | -1.51B | -820.00M |
Cash Flow | Free Cash Flow | |||
764.00M | 538.00M | 431.00M | 1.97B | 1.91B | Operating Cash Flow |
939.00M | 799.00M | 858.00M | 2.46B | 2.19B | Investing Cash Flow |
-513.00M | -260.00M | -420.00M | -481.00M | -258.00M | Financing Cash Flow |
-368.00M | -569.00M | -433.00M | -1.33B | -2.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $392.08B | 28.13 | 20.06% | 3.04% | -4.51% | 3.69% | |
72 Outperform | $145.71B | 18.25 | 9.05% | 6.57% | 8.77% | 272.80% | |
71 Outperform | $235.81B | 13.86 | 40.81% | 3.34% | 6.85% | 4577.79% | |
71 Outperform | $377.06B | 89.36 | 61.94% | 2.97% | 3.71% | -12.14% | |
65 Neutral | $4.02B | 4.68 | 429.85% | 7.47% | 2.24% | -16.11% | |
60 Neutral | $124.82B | ― | -39.10% | 4.05% | 7.32% | -214.24% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
Organon announced its financial results for the fourth quarter and full year of 2024, reporting annual revenue of $6.4 billion, a 2% increase as-reported, and a 3% increase at constant currency. Despite challenges like the loss of exclusivity for Atozet in certain markets, the company aims for continued growth in 2025, with a revenue projection of $6.125 to $6.325 billion. The fourth quarter of 2024 showed flat revenue compared to the previous year, with notable performance in women’s health due to Nexplanon growth and competitive pressures on biosimilars. The company’s net income saw a decrease due to a one-time tax benefit in 2023, while non-GAAP adjusted net income remained stable.
On January 15, 2025, Organon & Co. announced the cessation of Susanne Fiedler’s role as Chief Commercial Officer, though she will remain as a senior advisor until her expected departure on or about April 30, 2025. This change may impact the company’s strategic operations and leadership dynamics as it navigates the transition period.